Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Novocure Ltd (NVCR)  
$16.47 0.34 (2.11%) as of 4:30 Fri 5/10


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 101,800,000
Market Cap: 1.68(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $11.13 - $82.51
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   NovoCure is an oncology company with a platform technology called Tumor Treating Fields. Co. is focusing on commercial adoption of Optune and NovoTTF-100L. Optune is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with newly diagnosed glioblastoma (GBM) in combination with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Co. also has approval to market Optune for the treatment of GBM in the European Union, Japan and certain other countries. NovoTTF-100L is approved by the FDA to treat malignant pleural mesothelioma in combination with chemotherapies.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 10,224 10,224 13,200 434,026
Total Sell Value $164,332 $164,332 $235,406 $41,239,900
Total People Sold 2 2 4 10
Total Sell Transactions 6 6 11 52
End Date 2024-02-11 2023-11-10 2023-05-12 2022-05-12

   
Records found: 906
  Page 7 of 37  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Benaim Ely Chief Medical Officer   •       –      –    2022-01-06 4 A $63.82 $3,510 D/D 55 28,199     -
   Cordova Ashley Chief Financial Officer   •       –      –    2022-01-06 4 A $63.82 $2,936 D/D 46 41,804     -
   Weinberg Uri Chief Science Officer   •       –      –    2022-01-06 4 A $63.82 $2,234 D/D 35 31,815     -
   Burke William Patrick Chief Human Resources Officer   •       –      –    2022-01-06 4 A $63.82 $5,105 D/D 80 50,950     -
   Danziger Asaf Chief Executive Officer   •       •      –    2022-01-06 4 A $63.82 $1,978 D/D 31 13,307     -
   Burke William Patrick Chief Human Resources Officer   •       –      –    2022-01-03 4 AS $75.96 $300,263 D/D (3,951) 50,870 -24%     
   Burke William Patrick Chief Human Resources Officer   •       –      –    2022-01-03 4 OE $7.15 $299,996 D/D 28,604 51,269     -
   Cordova Ashley Chief Financial Officer   •       –      –    2021-11-02 4 S $107.28 $22,421 D/D (209) 41,758 34%     
   Shah Pritesh Chief Commercial Officer   •       –      –    2021-09-03 4 AS $138.27 $69,477 D/D (501) 73,512 -50%     
   Cordova Ashley Chief Financial Officer   •       –      –    2021-09-02 4 S $138.23 $114,456 D/D (828) 41,967 50%     
   Groenhuysen Wilhelmus Cm Chief Operating Officer   •       –      –    2021-09-02 4 S $138.23 $25,020 D/D (181) 149,899 50%     
   Leonard Frank X Chief Development Officer   •       –      –    2021-09-02 4 S $138.23 $74,645 D/D (540) 87,153 50%     
   Shah Pritesh Chief Commercial Officer   •       –      –    2021-09-02 4 AS $138.23 $21,564 D/D (156) 74,013 -50%     
   Burke William Patrick Chief Human Resources OfficerO   •       –      –    2021-09-01 3 IO $0.00 $0 D/D 0 15,934 -47%     
   Burke William Patrick Chief Human Resources OfficerO   •       –      –    2021-09-01 3 IO $0.00 $0 D/D 0 10,283 -47%     
   Cordova Ashley Chief Financial Officer   •       –      –    2021-08-12 4 GD $0.00 $0 D/D 1,733 44,260     -
   Cordova Ashley Chief Financial Officer   •       –      –    2021-08-12 4 S $140.90 $3,752,286 D/D (26,624) 45,993 41%     
   Cordova Ashley Chief Financial Officer   •       –      –    2021-08-12 4 OE $15.60 $1,055,329 D/D 36,624 48,599     -
   Madden Martin J. Director   –       •      –    2021-08-05 4 S $153.13 $5,206 I/I (34) 384 47%     
   Leung Gabriel Director   –       •      –    2021-08-05 4 AS $152.50 $152,500 D/D (1,000) 72,859 -47%     
   Leung Gabriel Director   –       •      –    2021-08-05 4 OE $31.45 $31,450 D/D 1,000 73,859     -
   Shah Pritesh Chief Commercial Officer   •       –      –    2021-08-04 4 AS $148.71 $306,789 D/D (2,063) 74,169 -43%     
   Shah Pritesh Chief Commercial Officer   •       –      –    2021-08-03 4 S $149.43 $247,157 D/D (1,654) 76,232 44%     
   Leonard Frank X Chief Development Officer   •       –      –    2021-08-03 4 S $149.43 $49,013 D/D (328) 89,158 44%     
   Benaim Ely Chief Medical Officer   •       –      –    2021-08-03 4 AS $150.11 $69,651 D/D (464) 28,144 -44%     
  906 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 7 of 37
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us